**Author Information** An event is serious (based on the ICH definition) when the patient outcome is:\* death\* life-threatening\* hospitalisation\* disability\* congenital anomaly\* other medically important event

A 60-year-old woman developed right bundle branch block and corrected QT interval (QTc) prolongation during an off-label treatment with hydroxychloroquine for severe acute respiratory distress syndrome coronavirus-2 (SARSCoV-2; COVID-19) \[*routes not stated*\].

The woman was admitted in Brunei following her nasopharyngeal and throat swabs tested positive (reverse transcriptase \[RT\]--PCR) for SARSCoV-2. She had a history of travel to Indonesia and was found linked to a confirmed COVID-19 case through contact tracing. She had comorbidities such as hypertension, hyperlipidaemia and being overweight. However, she had no known heart disease. Upon admission, her chest radiograph was normal. Laboratory investigations showed mildly elevated CRP without lymphopenia. An empirical treatment with amoxicillin/clavulanic acid was started with an off-label treatment with oseltamivir for SARSCoV-2. On hospital day 2, chest x-ray was repeated, which showed bilateral lower zone opacities. Consequently, she was transferred to ICU for close monitoring. Lopinavir/ritonavir 400/100mg was added to the off-label treatment. However, her condition did not improve. Hence, off-label hydroxychloroquine 400mg stat dose followed by 200mg twice daily was initiated on hospital day 4. An ECG on the same day prior to the initiation of hydroxychloroquine was normal (QTc of 397ms). On hospital day 5, repeat ECGs were also normal (QTc 414ms), however her condition worsened, and she needed intubation and ventilator support. Blood and urine cultures were negative, but sputum culture grew *Pseudomonas aeruginosa* and *Serratia marcescens.* Both were sensitive to meropenem. Consequently, treatment with amoxicillin/clavulanic acid was changed to meropenem. Inotropic support was started with norepinephrine \[noradrenaline\] and dopamine. On hospital day 5, serum troponin I was found to be mildly elevated. A transthoracic echocardiogram (TTE) exhibited normal ejection fraction with no regional wall motion abnormalities. Myocarditis secondary to SARS-CoV-2 was suspected. Twice daily serial monitoring of troponin I showed fluctuation. On hospital day 7, a repeat ECG prior to the morning dose of hydroxychloroquine revealed a new right bundle branch block and critically prolonged QTc (631ms).

The woman\'s treatment with hydroxychloroquine was stopped following a cumulative dose of 1400mg. Blood tests day the same day showed slightly low corrected Ca2+, which was corrected with calcium replacement. Twenty four hours following the discontinuation of hydroxychloroquine, a repeat ECG showed normalisation of the QTc (433ms). On hospital day 10, a repeat TTE exhibited normal cardiac function. Eventually, she was weaned-off norepinephrine and dopamine. On hospital day 14, she was extubated. Laboratory investigations on hospital day 19 showed improvement. Heparin was started. Following three successive negative RT-PCR results for SARS-CoV-2, she was transferred to a tertiary hospital on hospital day 23. A CT pulmonary angiogram exhibited scattered ground-glass opacities consistent with COVID-19. A small pulmonary embolism was noted on the right and dabigatran was started. At follow-up, she continued to be well.
